Hall of Fame For Pioneers
Takehiko Fujino,MD,PhD, is an Emeritus Professor of Kyushu University. He graduated from Medical School of Kyushu University, Japan, in 1964. He is strongly interested in the integrated medicine, especially in the correlation between brain and other organs although his specialty was initially cardiology of internal medicine.
He advocated a new concept “Brain Fatigue”, from which many kinds of diseases might be induced, and developed “BOOCS: Brain-Oriented Oneself-Care System”, a new method for removal of “Brain Fatigue” in 1991. It has been known that many kinds of disorders such as metabolic syndrome, depression and dementia were improved and then the death rate of those patients decreased by “BOOCS” method. As one of those researches, he has studied the correlation among “Brain Fatigue”, Alzheimer’s disease and plasmalogen.
Shiro Mawatari, MD, PhD, is a Director of Institute of Rheological functions of Food. He graduated from Medical School of Kyushu University (Fukuoka, Japan) in 1964, and was engaged in biochemical research on erythrocyte membrane of dystrophy at School of Medicine at the University of Pennsylvania (Philadelphia, USA) and Columbia Neuroscience, Columbia University (New York, USA) for three years and a half. After returning to Japan, he worked as an associate professor at Kyushu Institute of Technology (Fukuoka, Japan) and a professor at Fukuoka Women’s University (Fukuoka, Japan). In recent 15 years, he has been dedicated to developing technology for measurement and extraction, and to developing functional food from raw materials with its technology.
RESEARCH AND DEVELOPMENT
Takehiko Fujino, MD., PhD. Emeritus Professor, Kyushu University, the founder of BOOCS Medical Group, Japan had conducted the researches focusing on Plasmalogen replacement therapy, and reported positive outcomes from Scallop-extracted Plasmalogen which has been acknowledged world-wide HISTORY
Developed a method for measuring ether phospholipids in human serum by HPLC-ELSD method Ref:Lipids,51(8),997 1006 ,2016 Prove that plasmalogen activates Akt and ERK 1/2 via several orphan G protein-bound receptors Ref: PLos ONE. 2016 ,11: e0150846
Started open trials for people with moderate or sevior Alzheimer’s disease and other dementia symptoms on January.
Started large scale clinical trials for people with mild dementia(called as Alzheimer’s disease) for scallop derived Plasmalogen on November Succeeded in extracting high-purity plasmalogen derived from sallops. Safety test completed.
Prove that Plasmalogen suppresses apoptosis through activation of Akt and ERK 1/2 Ref: Los ONE 2013,8:e83508
Started research on double shellfish to find for the better materials.
Prove that erythrocyte Plasmalogen is reduced in patients with Alzheimer’s disease Ref: Dement Geriatr Cogn Disord Extra 2:298-303,2012 Patent pending 2010-001337 Prove that Plasmalogen administraion is effective in Alzheimer’s disease by animal model Remark: suppressess inflammation of brain nerve cells as well as amyloid-beta protein accumulation Ref: Journal of Neuro inflammation 9:197-209,2012 Prove that oral administration of Plasmalogen increases erythrocyte plasmalogen Ref: Lipids in Health and Disease 11:161 167,2012 Plasmalogen safety test completed.
Confirmation of safety and improvement effects of Alzheimer’s disease in human trial at medical institutions.
Successful sophystification of the Plasmalogen detection,Simplification method Ref:Analytical Biochemistry 370:54-59,2007
Discovered high purity plasmalogen extraction method from chicken meat Patent published 2006-23296 Patent. pending 2007-16056